Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma

The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell (CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current practice is guided through physician preference rather than established evidence. Identification of effective BT modalities and...

Descripción completa

Detalles Bibliográficos
Autores principales: Roddie, Claire, Neill, Lorna, Osborne, Wendy, Iyengar, Sunil, Tholouli, Eleni, Irvine, David, Chaganti, Sridhar, Besley, Caroline, Bloor, Adrian, Jones, Ceri, Uttenthal, Ben, Johnson, Rod, Sanderson, Robin, Cheok, Kathleen, Marzolini, Maria, Townsend, William, O'Reilly, Maeve, Kirkwood, Amy A., Kuhnl, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300297/
https://www.ncbi.nlm.nih.gov/pubmed/36724512
http://dx.doi.org/10.1182/bloodadvances.2022009019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300297/
https://www.ncbi.nlm.nih.gov/pubmed/36724512
http://dx.doi.org/10.1182/bloodadvances.2022009019

Ejemplares similares